Chimeric anti-CD20 (idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 3, 1997, Pages 177-186

  Demidem, Aicha ^a   Lam, Tammy ^a   Alas, Steve ^a   Hariharan, Kandasamy ^b   Hanna, Nabil ^b   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOGEN   (United States)

Author keywords

B lymphoma; CD20; Cytotoxicity; Sensitization

Indexed keywords

CD20 ANTIGEN; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; GENE PRODUCT; MONOCLONAL ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RICIN;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHIMERA; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; SENSITIZATION;

EID: 0030800131     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.177     Document Type: Article

References (26)

1. Brown SL, Miller RA, Homing SJ, Czerwinski D, Hart SM, McElderry R, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989;73:651-661.
2. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985;65:1349-1363.
3. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992;80:1502-1510.
4. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas Blood 1992;69:584-591.
5. 131I]anti-B1 (anti-CD20) antibody N Eng J Med 1993;329:459-465.
6. Stashenko P, Nadler LM, Hardy R, Schlossman, SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-1685.
7. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, et al Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989;169:2043-2058.
8. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas. A model of human B cell differentiation. Blood 1984;63:1424-1433.
9. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-777.
10. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994,83:435-445.
11. Maloney DG, Leler TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
12. Maloney DG, Grillo-Lopez AJ, Bodkin D, White C, Foon K, Schilder RJ, et al. IDEC-C2B8 anti-CD20 antibody: Results of long term follow-up of relapsed NHL phase II patients Blood 1995; 86:54a.
13. Ohnishi K, Bonavida B. Regulation of B-cell lymphoma growth in syngeneic SJL/J mice. Establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice. Leukemia 1993;7:1801-1806.
14. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis and drug resistance of human tumor cell lines by combination treatment with anti-fas antibody and drugs or toxins. Cancer Res 1993;53:2591-2596.
15. Safrit JT, Berek JS, Bonavida B. Sensitivity of drug resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-a) and doxorubicin. Failure of the combination to modulate the MDR phenotype. Gynecol Oncol 1992;48:214-220
16. Safrit JT, Belldegrun A, Bonavida B. Sensitivity of human renal cell carcinoma lines to TNF, adriamycin and combination: Role of TNF-mRNA induction in overcoming resistance. J Urology 1993;149:1202-1208.
17. Roos G, Berdel WE. Senstitivity of human hemotoporatic cell lines to an alkyl-lysophospholipid derivative. Leukocyte Research 1986;10:195-201.
18. Mitzutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809-818.
19. Gan XH, Robin JP, Mencia-Huerta JM, Braquet P, Bonavida B. Inhibition of TNF-α and IL-1β secretion but not IL-6 from activated human peripheral blood monocytes by a new synthetic de-methylpodophyllotoxin derivative. J Clin Immunol 1994,14 280-288.
20. Jewett A, Bonavida B. Target-induced split anergy and apoptosis in a subset of human natural killer cells. J Immunol 1996;156:907-915.
21. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
22. Morimoto H, Bonavida B. Diptheria-toxin and Pseudomonas A toxin-mediated apoptosis: ADP-ribosylation of EF-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-". J Immunol 1992;149:2089-2094.
23. Morimoto H, Bonavida B. Ricin-mediated cell lysis and apoptosis of drug sensitive and resistant tumor cells. Int J Oncol 1993;2:363-371.
24. Vitetta ES, Fulton RJ, Uhr JW. Cytotoxicity of a cell reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain. J Exp Med 1984;160:341-346.
25. Endicott JA, Ling V. The biochemistry of glycoprotein mediated muiltidrug resistance. Ann. Res Biochem 1989;58:137-171.
26. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-α. FASEB 1990; 4:3215-3223.